Arrowhead say-on-pay proposal fails at 2026 annual meeting; director Michael Perr receives 31% against votes

ARROWHEAD PHARMACEUTICALS, INC.

Say-on-pay proposal failed: 41.6M for, 60.0M against, 17.9M broker non-votes.
Director Michael Perr received 31.3M against votes (70.4M for), highest dissent of any nominee.
Amended 2021 Incentive Plan approved: 99.2M for, 2.4M against, 0.3M abstain.
KPMG ratified as auditor for FY2026: 119.1M for, 0.4M against, 0.4M abstain.
All other directors elected with over 90% support from votes cast (excluding broker non-votes).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.